Skip to content
Sora Lifesciences
Nordic cardiac MedTech startup

Validating clinical adoption for a novel cardiac monitoring system

Ran a rapid, statistically robust physician validation program across EU5 markets to test clinical relevance, workflow fit, and adoption potential for a new continuous cardiac monitoring and management system — turning an unproven concept into a quantified, evidence-backed value proposition.

Key offerings in this project
  • Concept Testing / Evaluation
  • Value Proposition Development / Testing
  • Disease & Clinical Care Pathway Intelligence

The brief

Validate clinical adoption for a novel continuous cardiac monitoring system across the EU5

  • Test recognition of the proposed clinical benefits
  • Measure willingness to adopt and willingness to pay
  • Locate the concept within the cardiovascular care pathway
  • Identify the workflow gaps a new device must address

The anticipated benefits had come from the engineering team, never from the clinic.

The problem

No physician evidence yet, and a decision on a tight clock — a multi-month field study was never an option

  • Statistically credible validation needed at speed
  • Benefits assumed internally, untested externally
  • Adoption drivers and blockers both unknown
  • Unclear where in the pathway the data changes a decision

The team was weeks, not months, from committing to a product direction.

Our approach

A five-minute express survey with EU5 cardiothoracic surgeons, run alongside a care-pathway mapping exercise

  • Express online survey with cardiothoracic surgeons across the EU5
  • Agreement tested against each proposed clinical benefit
  • Willingness to adopt and willingness to pay captured
  • Care-pathway mapping to pinpoint the decision points

Running the survey and the mapping in parallel is what compressed the timeline.

Key outcomes

A statistically robust, EU5-wide read on adoption potential and willingness to pay, inside the client's window

  • Several core benefits strongly validated by physicians
  • Prioritised list of which benefits to lead with commercially
  • Benefits still needing a real-world evidence base flagged
  • The pathway position where the technology is most credible

Uniform physician buy-in proved to be the wrong assumption to plan against.

Get in touch

Facing a similar challenge?

Tell us what decision you're facing. We'll turn it into a clear, evidence-backed answer.

© 2026 Sora Life Sciences. All rights reserved.